Sep 05, 2023 Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 10, 2023 Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Aug 01, 2023 Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
Jul 27, 2023 Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Jul 25, 2023 Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
May 12, 2023 Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Apr 17, 2023 Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
Mar 30, 2023 Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
Mar 08, 2023 Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
